ACTRN12607000455460
Active, Not Recruiting
N/A
A 12 week intervention examining the effect of fish oil on appetite, inflammatory markers and nutritional parameters in dialysis patients
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Kidney Disease
- Sponsor
- Queensland University of Technology
- Enrollment
- 30
- Status
- Active, Not Recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Adult chronic kidney disease patients aged \> 18 years who have been receiving hemodialysis for \> 3 months.
Exclusion Criteria
- •Taking a fish oil supplement providing \> 500 mg/day, aged \< 18 years, on hemodialysis \< 3 months, presence of emotional, cognitive or language limitations impairing their ability to provide informed consent or follow study instructions (where a carer or translator is not available).
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not Yet Recruiting
Phase 4
Impact of Follow up Counseling package on the Follow up Rate and Neonatal Outcomes of High Risk NeonatesHealth Condition 1: P070- Extremely low birth weight newbornCTRI/2019/08/020624Post graduate Institute of Nursing Education Chandigarh
Active, Not Recruiting
N/A
12 week Chronic Obstructive Pulmonary Disease (COPD)studysubjects with Chronic Obstructive Pulmonary Disease (COPD)MedDRA version: 14.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2010-024435-16-DEGlaxoSmithKline Research & Development Ltd248
Active, Not Recruiting
N/A
A 12-week study to evaluate the effect of the drug fluticasone furoate/vilanterol at the dose of 100/25 mcg Inhalation Powder delivered once daily via a Novel Dry Powder Inhaler (NDPI) on arterial stiffness compared with the drug Tiotropium bromide at the dose of 18 mcg delivered once daily via a HandiHaler in subjects with Chronic Obstructive Pulmonary Disease (COPD)EUCTR2010-024435-16-ITGlaxoSmithKline Research & Development Ltd248
Completed
Phase 4
A Pilot Study to Evaluate Efficacy and Safety of Fixed Dose Combination Capsules in Patients with GERD and Overlapping Symptoms of DyspepsiaHealth Condition 1: K219- Gastro-esophageal reflux disease without esophagitisCTRI/2020/09/027876Abbott India limited50
Recruiting
N/A
Quitting Using Incentives Trial for a HEaLthy Pregnancy (QUIT-HELP)ACTRN12623000922673niversity of Adelaide460